Board of Directors


Gert W. Munthe

Munthe is the founder and Managing Partner of Herkules - a leading Nordic private equity player. Munthe has more than 20 years’ experience as a senior executive from both Norwegian and international business. He was CEO of Alpharma 1998-2000, listed on the NYSE. He was CEO of NetCom in the period 1993 to 1998 and led the company to profitability four years after commercial launch. Prior to NetCom, he was Executive Vice President of Hafslund Nycomed and then CEO of Nycomed Imaging from 1988 to 1993. From 1983 to 1987 he worked for McKinsey & Company in Oslo and New York. Munthe was responsible for Pronova investments in Herkules. Pronova turned to be the world's leading supplier of Omega 3-based drugs. Munthe has extensive board experience.

Knut Eidissen

Eidissen is the owner and managing director of the consulting and investment company Picasso AS. Eidissen started his entrepreneurial career when he started the company in 2005, which he has gradually built up to become one of the largest private investment companies in Northern Norway. He has experience as a board member from both private as well as public limited companies. Eidissen has a good track record in creating shareholder value, e.g. as chairman of the oil-and oil service company, Altinex ASA, listed at the Oslo Stock Exchange. Altinex ASA was later acquired by Norwegian Energy Company ASA (Noreco). Eidissen is through Picasso Kapital AS, the largest shareholder in Lytix Biopharma AS.

John Sigurd Svendsen

Svendsen brings extensive research experience from work in medical biochemistry, synthetic organic chemistry and medicinal chemistry, specialising in antibacterial peptides. He is a co-founder in the company, head of IPR and serves as Senior advisor to management team. Dr. Svendsen received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø.

Kari Grønås

Grønås has 25 years of experience from pharmaceutical research and development in Norwegian pharmaceutical companies including Nycomed, Amersham, Photocure and Algeta. In Algeta she was Senior Vice President Operations and responsible for establishing and operating the production for development and commercial use. Grønås was also project manager for Xofigo and coordinated all the required activities to get drug approval worldwide. She has on several occasions met with the European and U.S. regulatory authorities.

Morten Jurs

Jurs has broad executive experience from the pharmaceutical sector as well as non-executive experience from several board positions from both public and private companies. Jurs joined Stamina Group AS (a leading Scandinavian Health and Lifestyle company) as CEO in 2013. Prior to Stamina, he was CFO in Pronova BioPharma ASA from 2006 to 2009, and from 2009 he led the company’s further development as CEO. Jurs brings with him a versatile experience portfolio from the pharma­ceuticals, and health and lifestyle industry. Jurs holds a Master of Science in Business and Economics/MBA from the University of Wyoming.

Lena Torlegård

Torlegård has been an advisor on corporate communication since 1998, mainly dealing with financial, corporate and crisis communication. She has worked with a number of Life Science companies, among others Sobi, Karo Bio, Orexo and Medivir, and several clients within other industries. Her record of accomplishment also encompasses around 15 IPO’s – Orexo possibly the most prominent within the Life Science sector. She has also advised extensively on communication to support fund raising and M&A. She is currently a member of the Board of Directors for Nanologica - drug delivery and analytical chromatography. Lena Torlegård holds a degree in Business Administration from Stockholm School of Economics.

Debasish F. Roychowdhury

Roychowdhury is an oncologist with a background in R&D, regulatory affairs and commercial operations and is a recognized leader in the pharmaceutical industry. He is President of Nirvan Consultants and serves in senior advisory roles for biotechnology companies. He is the acting CMO (Chief Medical Officer) for Ra Pharmaceuticals and was the CMO at Seragon Pharmaceuticals. From 2009 to 2013, Roychowdhury was Senior Vice President and Head of the Global Oncology Division at Sanofi. Prior to that, he was Vice President and head of Clinical Development at GlaxoSmithKline. Roychowdhury directed the Oncology global regulatory group at Eli Lilly and Company. During his tenure in industry, he has been involved in the approval of nine new drugs, several IND filings and supplementary approvals.